Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -57.96% is 13% below its 4-year average of -51.33%, around the middle of its 4-year range (-86.79%–-27.40%).
As of the fiscal period ended Tuesday, June 30, 2026. 12.56% above its 12-month average of -66.29%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -57.96%.
RETURN ON EQUITY (ROE)
-57.96%
RETURN ON EQUITY (ROE) AVG TTM
-66.29%
RETURN ON EQUITY (ROE) AVG 3Y
-55.38%
RETURN ON EQUITY (ROE) AVG 5Y
-51.33%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+12.56%
CURRENT VS 3Y AVG
-4.67%
CURRENT VS 5Y AVG
-12.92%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
-37.98%
vs the sector median at left
Pharvaris N.V.
Market Cap
$2.17B
Return on Equity (ROE)
-57.96%
TTM Avg
-66.29%
3Y Avg
-55.38%
5Y Avg
-51.33%
Market Cap
$2.17B
Return on Equity (ROE)
-37.82%
TTM Avg
-53.05%
3Y Avg
-23.57%
5Y Avg
8.38%
Market Cap
$2.13B
Return on Equity (ROE)
-43.55%
TTM Avg
-14.07%
3Y Avg
-80.41%
5Y Avg
-980.81%
Market Cap
$2.24B
Return on Equity (ROE)
N/A
TTM Avg
9.38%
3Y Avg
9.38%
5Y Avg
9.38%
Market Cap
$2.11B
Return on Equity (ROE)
9.17%
TTM Avg
8.21%
3Y Avg
8.13%
5Y Avg
7.80%
Market Cap
$2.11B
Return on Equity (ROE)
-98.56%
TTM Avg
-37.96%
3Y Avg
-71.53%
5Y Avg
-45.53%
Market Cap
$2.11B
Return on Equity (ROE)
-23.58%
TTM Avg
-182.08%
3Y Avg
-186.85%
5Y Avg
-151.51%
Market Cap
$2.28B
Return on Equity (ROE)
18.14%
TTM Avg
20.16%
3Y Avg
28.24%
5Y Avg
15.58%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pharvaris N.V. (PHVS) | $2.17B | -57.96% | -66.29% | -55.38% | -51.33% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.17B | -37.82% | -53.05% | -23.57% | 8.38% |
| GeneDx Holdings Corp. (WGS)vs › | $2.13B | -43.55% | -14.07% | -80.41% | -980.81% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.24B | N/A | 9.38% | 9.38% | 9.38% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 9.17% | 8.21% | 8.13% | 7.80% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | -98.56% | -37.96% | -71.53% | -45.53% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | -23.58% | -182.08% | -186.85% | -151.51% |
| Alvotech (ALVO)vs › | $2.08B | N/A | 23.18% | 49.13% | 48.50% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.28B | 18.14% | 20.16% | 28.24% | 15.58% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | -58.45% | -43.81% | -43.57% | -51.47% |
ROE
-58.0%
ROA
-53.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -57.96% |
| 2026-03-31 | -72.56% |
| 2025-12-31 | -63.46% |
| 2025-09-30 | -50.68% |
| 2025-06-30 | -86.79% |
| 2025-03-31 | -68.44% |
| 2024-12-31 | -52.99% |
| 2024-09-30 | -44.60% |
| 2024-06-30 | -35.32% |
| 2024-03-31 | -30.98% |
| 2023-12-31 | -27.40% |
| 2023-09-30 | -74.15% |
| 2023-06-30 | -54.60% |
| 2023-03-31 | -65.39% |
| 2022-12-31 | -51.96% |
| 2022-09-30 | -29.89% |
| 2022-06-30 | -28.26% |
| 2022-03-31 | -28.59% |
| 2020-12-31 | -26.04% |
| 2020-09-30 | -48.22% |
| 2020-06-30 | -61.55% |
| 2019-12-31 | -52.63% |
| 2019-09-30 | -156.62% |
| 2019-06-30 | -132.43% |
| 2019-03-31 | -114.61% |
| 2018-12-31 | -358.09% |
